Person:
BOZKURT, SÜHEYLA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

BOZKURT

First Name

SÜHEYLA

Name

Filters

2010 - 20182
Reset filters

Settings

Has files: true × Subject: CANCER ×

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Indefinite Azacitidine Treatment Until Progression May Provide Long-Term Disease Control in Elderly Patients with Acute Myelogenous Leukemia
    (AVES, 2018-09-21) BOZKURT, SÜHEYLA; Eser, Ali; Sezgin, Aslihan; Kara, Osman; Uyar Bozkurt, Suheyla
    The prognosis of acute myelogenous leukemia (AML) is poor in elderly patients. The mean survival rates at second and fifth years for AML were 10% and 2%, respectively. Here our aim was to demonstrate that the survival rate can be prolonged by long-term azacitidine (AZA) treatment. Complete remission was achieved at the end of the fourth and sixth courses of AZA treatment in three elderly patients with AML with a high blast count. The first patient was followed without any treatment after getting complete remission with four courses of AZA, and at the end of 1 year follow-up, the patient died due to pneumonia. Complete remission was obtained in the second and third patients after four and six courses of AZA, respectively. Second patient is still being followed up in complete remission at the end of the 20th course of AZA. Recurrence occurred at the end of the 16th AZA course in the third patient and he died after 20 months of the treatment. In elderly patients with AML with a high blast count, the continuation of AZA treatment improves the overall survival rates.
  • Thumbnail Image
    PublicationOpen Access
    Expression and prognostic significance of cox-2 and p-53 in hodgkin lymphomas: a retrospective study
    (BMC, 2010-12) BOZKURT, SÜHEYLA; Barisik, Nagehan O.; Bozkurt, Suheyla; Gumus, Mahmut; Kaygusuz, Isik; Karadayi, Nimet; Bas, Emine; Bayik, Mahmut; Tecimer, Tulay
    Background: Cyclooxygenase (cox) is the rate-limiting enzyme, which catalyzes the conversion of arachidonic acid into prostaglandins and contributes to the inflammatory process. Cyclooxygenase-2 (cox-2), which is one of the two isoforms, plays a role in tumor progression and carcinogenesis. p53 contributes to apoptosis, DNA renewal and cell cycle. Studies concerning the relationship of cox-2 and p53 expressions and carcinogenesis are available, but the association between cox-2 and p53 in Hodgkin lymphoma (HL) is not exactly known. In our study, we examined the association of cox-2 and p53 expression, with age, stage, histopathological subtype, and survival in HL. We also examined correlation between cox-2 and p53 expression. Methods: Cox-2 and p53 expressions in Hodgkin-Reed Sternberg cells (HRS) were examined in 54 patients with HL depending on cox-2 expression, stained cases were classified as positive, and unstained cases as negative. Nuclear staining of HRS cells with p53 was evaluated as positive. The classifications of positivity were as follows: negative if<10%; (1+) if 10-25%; (2+) if 25-50%; (3+) if 50-75%, (4+) if >75%. Results: Cox-2 and p53 expressions were found in 49 (80%) and 29 (46%) patients, respectively. There were differences between histological subtypes according to cox-2 expression (p = 0.012). Mixed cellular (MC) and nodular sclerosing (NS) subtypes were seen most of the patients and cox-2 expression was evaluated mostly in the mixed cellular subtype. There were no statistically significant relationships between p53 and the histopathological subtypes; or between p53, cox-2 and the factors including stage, age and survival; or between p53 and cox-2 expression (p > 0.05). Conclusion: Considering the significant relationship between the cox-2 expression and the subtypes of HL, cox-2 expression is higher in MC and NS subtypes. However the difference between these two subtypes was not significant. This submission must be advocated by studies with large series